 |
|
|
October 31, 2007
Teikoku Seiyaku Co., Ltd
Torii Pharmaceutical Co., Ltd. |
|
|
Future Marketing and Distribution Organization for Dovonex® Ointment for
the Treatment of Psoriasis Vulgaris |
|
"Dovonex® Ointment" (generic name: calcipotriol ointment) for the treatment of psoriasis vulgaris is now jointly marketed and distributed by Teikoku Medix Co., Ltd., a subsidiary of Teikoku Seiyaku Co., Ltd. (Head Office: Kagawa Prefecture, President: Shosaku Murayama; hereinafter referred to as "Teikoku Seiyaku"), Astellas Pharma, Inc. (Head Office: Tokyo, President: Masafumi Nogimori; hereinafter referred to as "Astellas"), and Torii Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Norihiko Matsuo; hereinafter referred to as "Torii"). It was announced today that since Astellas will discontinue the marketing and distribution of the drug on December 31, 2007, Teikoku Medix and Torii will jointly perform the sales and information distribution activities of the ointment from January 1, 2008.
Dovonex® Ointment is a skin cream based on an active form of vitamin D3 developed by Teikoku Seiyaku in Japan under the license from LEO Pharma A/S of Denmark. Teikoku Seiyaku obtained approval to import the drug on January 18, 2000.
[Reference: Outline of "Dovonex® Ointment"]
Product name: Dovonex® Ointment
Concentration of active ingredient: 50 μg of calcipotriol/g
Indication: Psoriasis vulgaris
| Dosage and administration: |
Usually, an appropriate amount of the drug is applied to the affected area twice daily. |
Packaging: 10 and 30 g
Launch date: June 2000
NHI (reimbursement) price: 0.005% 1 g: 141.90 Yen (after NHI price revision in April 2006)
Manufacturer/distributor: Teikoku Seiyaku Co., Ltd. |
|
|
| |
|
|
|
|
